Drugs / Magnesium Isoglycyrrhizinate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02734966 | Dec 2007 → Dec 2008 | drug-induced liver injury | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03349008 | Nov 2017 → Dec 2019 | chronic hepatitis B virus infection | Cttq | Unknown | No outcome recorded |
| Phase 4 | NCT01802996 | Mar 2013 → Aug 2014 | drug-induced liver injury, neoplasm | Cttq | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT07150624 Background | Nov 2025 → Dec 2026 expected | hepatocellular carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04595916 Comparator | Apr → Oct 2020 | drug-induced liver injury | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06922669 Background | Jun 2025 → Mar 2027 expected | drug-induced liver injury | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magnesium Isoglycyrrhizinate | “And 930mg of polyene phosphatidylcholine injection,twice a day, combined with 100mg of magnesium isoglycyrrhizinate injection once a day，from the 1st to the 5th day after the operation.” NCT07150624 ↗ |
| Known as | 18.alpha.-glycyrrhizin magnesium | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297780 ↗ |
| Route | Intravenous | “200mg IV on day 1-5” NCT01802996 ↗ |